Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Kentucky: - Flaget Memorial Hospital — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Saint Joseph Hospital — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Kentucky: - Flaget Memorial Hospital — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Saint Joseph Hospital — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in Kentucky: - Flaget Memorial Hospital — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Saint Joseph Hospital — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 3 Recruiting Industry
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…
Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in Kentucky: - Norton Cancer Institute, St. Matthews Campus — Louisville, Kentucky
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 3 Recruiting Industry
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …
Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in Kentucky: - Research Site — Louisville, Kentucky
Phase 3 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07258511
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 3 Recruiting Industry
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05730036
Sites in Kentucky: - University of Kentucky, Markey Cancer Center Clinical Research Organization — Lexington, Kentucky
- Norton Cancer Institute — Louisville, Kentucky
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Kentucky: - Norton Women's and Children's Hospital — Louisville, Kentucky
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively trea…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03761108
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT04634552
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 1, Phase 2 Recruiting Industry
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem c…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05828511
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 1 Recruiting Industry
The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose …
Sponsor: C4 Therapeutics, Inc.
NCT ID: NCT07280013
Sites in Kentucky: - Norton Cancer Institute St. Matthews — Louisville, Kentucky
Phase 1 Recruiting Industry
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to as…
Sponsor: Caribou Biosciences, Inc.
NCT ID: NCT05722418
Sites in Kentucky: - University of Kentucky/ Markey Cancer Center — Lexington, Kentucky
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kentucky: - Flaget Memorial Hospital — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Saint Elizabeth Healthcare Edgewood — Edgewood, Kentucky
- Saint Elizabeth Healthcare Fort Thomas — Fort Thomas, Kentucky
- Saint Joseph Hospital — Lexington, Kentucky
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Kentucky: - University of Louisville Hospital - James Brown Cancer Center — Louisville, Kentucky
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Kentucky: - Baptist Corbin — Corbin, Kentucky
- Baptist Hardin — Elizabethtown, Kentucky
- Baptist Lexington — Lexington, Kentucky
- Baptist Paducah — Paducah, Kentucky